KCNQ2 and Epileptic encephalopathy: Everolimus, an mTOR inhibitor, has shown clinical efficacy in WS associated with TSC1/TSC2 mutations, while NMDA receptor antagonists, such as memantine, and potassium-channel openers, like retigabine, are currently being investigated for their potential in GRIN2A/GRIN2B and KCNQ2-related epileptic encephalopathies, respectively [39].